Company intelligence / Profile preview

Lewwin

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Lewwin Pharma is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic disorders, particularly hyperuricemia and gout, as well as oncology. Its lead program, LW-402, is a potent and selective URAT1 inhibitor designed to lower serum uric acid levels with a favorable safety profile. Lewwin maintains an integrated R&D platform that spans from drug discovery to clinical development. The company aims to provide high-quality, affordable innovative medicines for patients globally.

Therapeutic areas: RheumatologyMetabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Lewwin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lewwin.

Explore the full profile